Dr. Chaft on Immune-Related AEs in NSCLC

Jamie E. Chaft, MD, discusses immune-related adverse effects in non–small cell lung cancer.

Jamie E. Chaft, MD, thoracic medical oncology, Memorial Sloan Kettering Cancer Center, discusses immune-related adverse effects (irAEs) in non–small cell lung cancer (NSCLC).

Understanding when irAEs are likely to occur and how to mediate them could inform when it is safe to restart a patient on immunotherapy, explains Chaft.

Historically, irAEs were thought to be exclusively mediated by T cells, says Chaft. However, it is now understood that although some irAEs are mediated by T cells, others such as thyroiditis are likely mediated by B cells. Some irAEs may also be mediated by cytokine events.

Deciding when to restart a patient on immunotherapy depends on the severity of irAEs, explains Chaft. Additionally, the duration and impact irAEs have on patients varies.

Related Videos
William M. Sikov, MD
Pannaga G. Malalur, MBBS
Gautam Borthakur, MD
Dimitrios Nasioudis, MD, physician, fellow, gynecologic oncology, Department of Obsetrics and Gynecology, University of Pennsylvania, Penn Medicine
Brian M. Slomovitz, MD
Shannon N. Westin, MD, MPH, FACOG
Pamela T. Soliman, MD, MPH
Martin F. Dietrich, MD, PhD, medical oncologist, Florida Cancer Specialists & Research Institute
Bruno B. Bockorny, MD
Mansoor Raza Mirza, MD
Related Content